Current status of HIV infection: A review for non-HIV-treating physicians

International Journal of Dermatology

Volumn 46, Issue 12, 2007, Pages 1219-1228

  Knoll, Bettina ^a,b   Lassmann, Britta ^a   Temesgen, Zelalem ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; AMPRENAVIR PHOSPHATEPLUS RETONAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INDINAVIR; INFLUENZA VACCINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; POLYSACCHARIDE VACCINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR PLUS LAMIVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HEPATITIS A; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFLUENZA; MORBIDITY; MORTALITY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS JIROVECI; REVIEW; STREPTOCOCCUS PNEUMONIA; SURVIVAL RATE; TOXOPLASMA GONDII;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; PRACTICE GUIDELINES AS TOPIC; VIRAL LOAD;

EID: 37549031699     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03520.x     Document Type: Review

References (74)

1. World Health Organization (WHO). AIDS Epidemic Update: December 2006. URL http://www.unaids.org/en/HIV_data/epi2006/default.asp. [accessed on 21 May 2007].
2. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20: 1447-1450.
3. United States Centers for Disease Control and Prevention. HIV/AIDS United States, 1981-2006. MMWR Morb Mortal Wkly Rep 2006; 55: 588-605.
4. United States Centers for Disease Control and Prevention. Glance at the HIV/AIDS Epidemic. April 2006. URL http://www.cdc.gov/hiv/resources/ factsheets/At-A-Glance.htm. [accessed on 21 May 2007].
5. United States Centers for Disease Control and Prevention. Fact Sheet: HIV/AIDS Among Men Who Have Sex With Men. January 2006. URL http://www.cdc.gov/hiv/topics/msm/resources/factsheets/msm.htm. [accessed on 21 May 2007].
6. United States Centers for Disease Control and Prevention. Fact Sheet: HIV/AIDS Among African Americans. February 2006. URL http://www.cdc.gov/ HIV/topics/aa/resources/factsheets/aa.htm. [accessed on 21 May 2007].
7. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
8. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336: 1531-1532.
9. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART eras. J Acquir Immune Defic Syndr 2006; 41: 194-200.
10. Haseltine WA. Molecular biology of the human immunodeficiency virus type 1. FASEB J 1991; 5: 2349-2360.
11. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 2006. URL http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf. [accessed on 21 May 2007].
12. World Health Organization (WHO). Progress on Global Access to Antiretroviral Therapy. March 2006. WHO Press Release. URL http://www.who.int/mediacentre/news/releases/2006/pr13/en/index.html. [accessed on 21 May 2007].
13. World Health Organization (WHO). Three Million by 2005. Making it Happen. The WHO Strategy. URL http://www.who.int/3by5/publications/ documents/en/3by5StrategyMakingItHappen.pdf. [accessed on 21 May 2007].
14. WHO HIV/AIDS Program. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Towards Universal Access. Recommendations for a Public Health Approach. August 2006. URL http://www.who.int/hiv/pub/guidelines/ adult/en/index.html. [accessed on 21 May 2007].
15. Sharifi-Mood B, Alavi-Naini R, Salehi M, et al. Spectrum of clinical disease in a series of hospitalized HIV-infected patients from southeast of Iran. Saudi Med J 2006; 27: 1362-1366.
16. United States Centers for Disease Control and Prevention, Castro KG, Ward JW, et al. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults 1993. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17): 1-19. URL http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. [accessed on 21 May 2007].
17. United States Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. MMWR Morb Mortal Wkly Rep 2002; 51 (RR-8): 1-46. URL http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr5108a1.htm. [accessed on 21 May 2007].
18. Corbett EL, Marston B, Churchard GJ, et al. Tuberculosis in sub-Saharan Africa: Opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367: 1817-1818.
19. Reid A, Scano F, Getahun H, et al. Towards universal access to HIV prevention, treatment, care, and support: The role of tuberculosis/HIV collaboration. Lancet Infect Dis 2006; 6: 483-495.
20. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231-235.
21. World Health Organization (WHO). World Health Organization Joint HIV/ Tuberculosis Interventions 2007. URL http://www.who.int/hiv/topics/tb/. [accessed on 21 May 2007].
22. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1997; 126: 123-132.
23. American Thoracic Society, CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Care Med 2000; 161: S221-S247.
24. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: Global trends and interactions with HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
25. Ahmed AB, Abubakar I, Delpech V, et al. The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales. Thorax 2007; 62: 672-676.
26. Shah NS, Wright A, Bai G-H, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387. URL http://www.cdc.gov/EID/content/13/3/380.htm. [accessed on 21 May 2007].
27. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
28. Maher D, Floyd K, Raviglione M, for the TB/HIV Working Group of the Global Partnership to Stop TB. Strategic Framework to Decrease the Burden of TB/HIV. Geneva, Switzerland: World Health Organization, 2002. URL http://whqlibdoc.who.int/hq/2002/WHO_CDS_TB_2002.296.pdf. [accessed on 21 May 2007].
29. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362: 22-29.
30. McNaghten AD, Hanson DL, Jones JL, et al. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999; 13: 1687.
31. Braithwaite RS, Justice AC, Chang CC, et al. Estimation of the proportion of patients infected with HIV who will die of comorbid disease. Am J Med 2005; 118: 890-898.
32. King JT Jr, Justice AC, Roberts MS, et al. Collaboration in HIV outcomes research - US Program Team long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making 2003; 23: 9-20.
33. Fang CT, Chang YY, Hsu HM, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. Q J Med 2007; 100: 97-105.
34. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
35. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
36. Jaggy C, von Overbeck J, Ledergerber B, et al. Mortality in the Swiss HIV cohort study (SHCS) and the Swiss general population. Lancet 2003; 362: 877-878.
37. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART eras. J Acquir Immune Defic Syndr 2006; 41: 194-200.
38. Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Virol Hepatitis 2007; 14: 183-188.
39. Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998; 27: 1510-1513.
40. Lu TH, Chang HJ, Chen LS, et al. Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan. J Formosan Med Assoc 2006; 7: 604-609.
41. 4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
42. 4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001; 13: 483-488.
43. Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: Validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42: 1639-1646.
44. Zhou J, Ditangco R. Predicting immune reconstitution syndrome. Clin Infect Dis 2007; 44: 147-148.
45. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Med 1998; 158: 157-161.
46. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-373.
47. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19: 399-406.
48. Michailidis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10: 417-422.
49. Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53: 357-363.
50. Bonnet MM, Pinoges LL, Varaine FF, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006; 20: 1275-1279.
51. Colebunders R, John L, Huyst V, et al. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006; 10: 946-953.
52. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: Spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41: 1483-1497.
53. Stone SF, Price P, Tay-Kearney M-L, et al. Cytomegalovirus retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune response within a predominant Th2 cytokine environment. J Infect Dis 2002; 185: 1813-1817.
54. Karavellas MP, Azen SP, Macdonald JC, et al. Immune recovery vitritis and uveitis in AIDS: Clinical predictors, sequelae, and treatment outcomes. Retina 2001; 21: 1-9.
55. Shelburne SA, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5: 67-79.
56. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-1627.
57. Filippini P, Coppola N, Pisapa R, et al. Impact of occult hepatitis B virus infection in HIV patients naïve for antiretroviral therapy. AIDS 2006; 20: 1253-1260.
58. Shelburne SA, Darcourt J, White C, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 1049-1052.
59. Barry SM, Lipman MC, Deery AR, et al. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002; 3: 207-211.
60. Jimenez-Exposito MJ, Alonso-Villaverde C, Sarda P, et al. Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy. AIDS 1999; 13: 152-153.
61. Gilad J, Borer A, Hallel-Halevy D, et al. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in a patient infected with Leishmania infantum. J Infect 2000; 40: 199-202.
62. Berry A, Abraham B, Dereure J, et al. Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy. Scand J Infect Dis 2004; 36: 225-227.
63. Posada-Vergara MP, Lindoso JA, Tolezano JE, et al. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005; 192: 1819-1822.
64. de Silva S, Walsh J, Brown M, et al. Symptomatic Schistosoma mansoni infection as an immune restoration phenomenon in a patient receiving antiretroviral therapy. Clin Infect Dis 2006; 42: 303-304.
65. Lanzafame M, Faggian F, Lattuada E, et al. Strongyloidiasis in an HIV-1-infected patient after highly active antiretroviral therapy-induced immune restoration. J Infect Dis 2005; 191: 1027.
66. Tsambiras PE, Larkin JA, Houston SH. Case report of Toxoplasma encephalitis after initiation of HAART. AIDS Read 2001; 11: 615-616.
67. Huttner H, Kollmar R, Hug A, et al. Fatal tuberculous meningitis caused by immune restoration disease. J Neurol 2004; 251: 1522-1523.
68. Lehloenya R, Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol Clin 2006; 24: 549-570.
69. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1: 107-115.
70. Ratnam I, Chiu C, Kandala NB, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42: 418-427.
71. Jevtovic DJ, Salemovic D, Ranin J, et al. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6: 140-143.
72. Sarazin E, Nacher M, Toure Y, et al. Dermatologic manifestations associated with immune reconstitution syndrome in HIV+ patients starting HAART: A retrospective study in French Guiana. Bull Soc Pathol Exot 2005; 98: 187-192.
73. Gray F, Bazille C, Adle-Biassette H, et al. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005; 11 (Suppl. 3): 16-22.
74. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: A decision analysis. J Acquir Immune Defic Syndr 2007; 44: 229-234.